mechanism of action of glp-1 receptor agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Frontiers | Mechanisms of action

Compared to the GLP-1 cohort, the tirzepatide group was younger (mean age 55.1 years vs

Diabetes: a tipping point in neurodegenerative diseases

Neurogenesis is defective in the AD model, which is characterized by decreased proliferation and differentiation, diminished neuronal maturity, and reduced survival, before processes that may secondarily affect neurogenesis, such as neuronal loss, amyloid deposition, and inflammation

GLP-1 treatment was not statistically significantly different compared to control at reducing the risk of developing dry AMD at one and three years after treatment, but GLP-1 receptor agonists did lower dry AMD risk at five and 10 years after treatment by 9.2% and 14.9%, respectively